Logo

Theravance Biopharma, Inc.

TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (J… read more

Healthcare

Biotechnology

9 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$14.07

Price

+2.03%

$0.28

Market Cap

$708.583m

Small

Price/Earnings

58.6x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$77.205m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$13.031m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

$0.24

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$224.848m

$426.035m

Assets

$201.187m

Liabilities

$46.457m

Debt
Debt to Assets

10.9%

1x

Debt to EBITDA
Free Cash Flow

$244.776m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases